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ABSTRACT
BACKGROUND: Aortic stiffness assessed by brachio-ankle pulse wave velocity
(baPWV) can be used to predict cardiovascular events. However, baPWV is depen-
dent on blood pressure. Antihypertensive drugs have been reported to reduce baPWV;
but it is difficult to determine if this effect is associated with lowered blood pressure
or reduced arterial stiffness.
OBJECTIVES: The primary end point of this study was to assess whether antihy-
pertensive drugs reduce arterial stiffness as estimated by cardio-ankle vascular index
(CAV!). The secondary end point was to compare the effects of 2 widely used drugs,
the calcium-channel blocker amlodipine and the angiotensin II receptor blocker can-
desartan, on arterial stiffness.
METHODS: Between October 2005 and September 2006, consecutive Japanese
outpatients with essential hypertension (EHT) (defined as using antihypertensive
drugs at screening, systolic blood pressure [SBP} >140 mm Hg, or diastolic BP
[DBP} >90 mm Hg) were assigned to treatment for 24 weeks with either amlodipine
(5-10 mg/d) or candesartan (8-12 mg/d). Arterial stiffness was evaluated with CAVI
before and after 24 weeks of treatment. Relative change in arterial stiffness from base-
line was also compared. The evaluator was blinded to treatment.
RESULTS: Twenty patients (11 men, 9 women; mean [SD} age, 62 [l0} years)
were included in the study. There were no significant differences in clinical character-
istics between the 2 groups. At baseline, mean (SD) CAVI was not significantly dif-
ferent in the amlodipine group compared with the candesartan group (8.93 [0.93} vs
8.46 [l.34}, respectively). During the 24-week treatment period, mean SBP and DBP
decreased significantly in both the amlodipine (14/10 mm Hg; P = 0.006 and P =
0.005) and the candesartan groups (13/11 mm Hg; P = 0.033 and P = O,()05). Am-
lodipine was associated with a significant change in CAVI from baseline (8.93 [O.93}
vs 8.60 [l.50}; P = 0.017), whereas candesartan was not (8.46 [l.34} vs 8.81 [l.20}).
The percentage change in CAVI was significantly different in the amlodipine
group compared with the candesartan group (-7.14 [8.83} vs 5.85 [16.0}, respec-
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tively; P = 0.038). After 24 weeks of treatment, the CAVI of the amlodipine group
was still numerically larger than baseline CAVI of the candesartan group, although
the difference was not statistically significant. Furthermore, there was no signifi-
cant difference in absolure CAVI between the 2 groups after 24 weeks, bur the rela-
tive change from baseline was significant in favor of amlodipine. Logistic regression
analysis revealed that amlodipine improved CAVI independent of its antihyperten-
sive effect.
CONCLUSION: These data suggest that amlodipine and candesartan had differ-
ent effects on aortic stiffness estimated by CAVI, despite similar effects on brachial
blood pressure after 24 weeks of treatment in these Japanese patients with EHT. (Curr
Ther Res Clin Exp. 2008;69:412-422) © 2008 Excerpta Medica Inc.
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INTRODUCTION
Arterial stiffness increases with age and is associated with pathological conditions,
including hypertension, diabetes mellitus, and end-stage tenal disease. 1.2 It is also
considered a marker for cardiovascular risk factors and organ damage.3-5
Carotid-femoral pulse wave velocity (cfPWV) is used to evaluate arterial stiffness,
but a femoral artery transducer adjusted to obtain an accurate pulse wave is required.
Brachio-ankle PWV (baPWV) is a more convenient index for evaluating arterial stiff-
ness. However, a problem with the clinical use of baPWV is its strong dependence on
blood pressure during measurement.6 To overcome this disadvantage, a stiffness diag-
nostic parameter called the cardio-ankle vascular index (CAV!) was developed in
Japan.7,8 Hayashi et al9 proposed the stiffness parameter ~, which represents the local
stiffness of a blood vessel. The parameter is based on a change in vascular diameter
(~D) corresponding to arterial pressure. Kawasaki et apo defined ~ as follows:
In (Ps/Pd) X D/~D,
where In is the natural log, Ps is systolic arterial pressure, and Pd is diastolic arterial
pressure. The formula enabled the measurement of Pwith an echo-phase tracking
system. Using this algorithm, the CAVI formula was created.8
We reported previously that CAVI was closely correlated with other stiffness parame-
ters, such as the stiffness Pand cross-sectional distensibility coefficients estimated by
carotid ultrasonography in patients with essential hypertension (EHT).11 An association
has also been found between CAVI and carotid intima-media thickness9 and left ven-
tricular diastolic function. 12 These results indicate that, similar to baPWV, CAVI might
be a useful clinical marker for evaluating atherosclerosis and arteriosclerosis.6
Angiotensin II receptor blockers (ARBs) were reported to reduce arterial stiffness
estimated by baPWV in hypertensive patients. 13 However, because measurement of
baPWV is highly dependent on blood pressure, it is difficult to know whether the im-
provement in arterial stiffness associated with antihypertensive drugs is mediated by
their blood pressure-lowering effects or is a result of the direct effects on blood vessels.
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Calcium channel blockers (CCBs) are commonly used antihypertensive drugs in
Japan. 14 Long-acting CCBs reduce the incidence of major cardiovascular events, espe-
cially stroke. 1S- 17 Amlodipine was found to reduce adverse cardiovascular events in
normotensive patients with coronary artery disease, whereas the angiotensin-converting
enzyme inhibitor enalapril had no such effect. IS Amlodipine may have a cardio-
vascular protective effect in addition to its strong blood pressure-lowering action. It
has been reported to have several blood pressure-independent effects, including anti-
oxidant activity,19 antiproliferative effects in vascular smooth muscle cells,2o and en-
hanced production of endothelial nitric oxide. 21
The primary end point in this study was to assess whether antihypertensive drugs
reduce arterial stiffness estimated by CAVI in Japanese patients with EHT. The
secondary end point was to compare the effects on arterial stiffness of 2 widely used
drugs, the CCB amlodipine and the ARB candesartan.
PATIENTS AND METHODS
STUDY PATIENTS
The ethics committee of Ehime University Hospital, Ehime, Japan, approved the
study, and written informed consent was obtained from all srudy participants. Study
participants were recruited consecutively from among patients with EHT who at-
tended the outpatient hypertension clinic at Ehime University Hospital between
October 2005 and September 2006. Essential hypertension was defined as the use of
antihypertensive drugs at screening, systolic blood pressure (SBP) >140 mm Hg,
or diastolic BP (DBP) >90 mm Hg expressed as the average of 3 measurements taken
in the seated position using a brachial automated sphygmomanometer (HEM
9000-AI, Omron, Kyoto, Japan).
Patients with congestive heart failure, previous myocardial infarction, angina pectoris,
atrial fibrillation, chronic renal failure (serum creatinine concentration> 1.5 mg/dL), pe-
ripheral arterial disease (ankle-brachial index <0.9), or a history of stroke were excluded
from the study. Patients taking antihypertensive drugs at screening entered a washout pe-
riod of~2 weeks. Medications other than antihypertensive drugs were allowed to be contin-
ued, although no changes in these regimens were permitted during the srudy period.
After baseline measurements of blood pressure and CAVI were obtained, eligible
patients were assigned to either the amlodipine or candesartan group. A pseudo-
randomization method was employed; patients with even medical record numbers were
assigned to the amlodipine group and those with odd numbers were assigned to the can-
desartan group. Patients in the amlodipine group received 5 mg of amlodipine once daily
and those in the candesartan group received candesartan 8 mg once daily as a starting dose.
In patients whose blood pressure was not controlled after 4 weeks (SBP >140 mm Hg and/
or DBP >90 mm Hg), the dose of amlodipine or candesartan was titrated to 10 or
12 mg, respectively. Evaluation of the patients, including blood pressure, heart rate, mea-
surement of biochemical markers, and adverse events, was conducted every 4 weeks at the
srudy visits. Compliance was also determined at this time. Outpatients were evaluated by
the lead study investigator (M.K.) who was blinded to treatment. CAVI was remeasured
at the end of the 24-week treatment period.
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MEASUREMENT OF CARDIO-ANKLE VASCULAR INDEX
The patients were placed in the supine position for ~10 minutes and then electro-
cardiography and phonocardiography were performed. baPWV was calculated by
dividing the distance from the aortic valve to the ankle artery by the sum of the dif-
ference between the time a pulse wave was transmitted to the brachium and the time
the same wave was transmitted to the ankle, and the time difference between the
second heart sound on phonocardiography and the notch of the brachial pulse waves
(VaSera VS-I000; Fukuda Denshi, Tokyo, ]apan).6-8 The formula used to calculate
CAVI was as follows8 :
CAVI = a ([2p/~P} X In [SBPIDBP} X baPWV2) + b,
where p is blood density, !1P is SBP - DBP, and a and b are constants to match aortic
PWV according to the method of Hasegawa. 22 This equation was derived from the
Bramwell-Hill equation23 and the stiffness parameter ~.9 CAVI reflects the stiffness
of the aorta and the femoral and tibial arteries as a whole and, theoretically, is not af-
fected by blood pressure.8 These measurements and calculations were done automati-
cally at the same time. BP was measured at the brachial artery. The average CV for the
CAVI measurement has been reported to be 3.8%.6,8
STATISTICAL ANALYSIS
All values are expressed as mean (SD). The baseline characteristics of the pa-
tients enrolled in the 2 treatment groups were compared using the unpaired t test,
the Mann-Whitney U test, or the X2 test. Changes in SBP, DBP, and CAVI be-
tween baseline and the end of the 24-week treatment period were analyzed using
paired t tests. Logistic regression analysis was carried out to determine the inde-
pendent prescriptive factor for improvement in CAVI. The relative change in
CAVI was analyzed by unpaired t test. We defined a decrease in baseline CAVI
after 24 weeks as state 1 and used study drug and ~SBP (treatment SBP - baseline
SBP) as the covariants. A sample size of ~25 patients was considered sufficient.
The odds ratios (ORs) were then calculated. P < 0.05 was considered statistically
significant.
RESULTS
CHARACTERISTICS OF THE STUDY PARTICIPANTS
Twenty patients (11 men, 9 women; mean [SD} age, 62 [l0} years) were in-
cluded in the study and evenly assigned to the 2 groups. All baseline demo-
graphic and clinical characteristics were similar between the 2 treatment groups
(Table). In both groups, 3 patients were receiving ~-blockers until 2 weeks be-
fore starting this study. One patient in the candesartan group was being treated
with an antiplatelet drug. Three patients in the amlodipine group and 2 patients
in the candesartan group had diabetes mellitus. No patients were withdrawn
from the study for any reason, and no cardiovascular events were reported during
the study.
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Table. Baseline demographic and clinical characteristics of outpatients with essential
hypertension (N = 20).*
Treatment
Amlodipine Candesartan
Characteristic (n = 10) (n = 10)
Age, mean (SD), y 61 (12) 62 (9)
Sex, no. (%)
Male 6 (60) 5 (50)
Female 4 (40) 5 (50)
Body mass index, mean (SO), kgjm2 25.7 (4.9) 24.8 (2.4)
Ouration of hypertension, mean (SO), y 8 (4) 7 (5)
Oiabetes mellitus, no. (%)t 3 (30) 2 (20)
Smoking status, no. (%)'1'
Current 2 (20) 2 (20)
Past 2 (20) 2 (20)
Never 6 (60) 6 (60)
Blood pressure, mean (SO), mm Hg
Systolic 150 (17) 152 (18)
Oiastolic 93 (13) 91 (15)
Pulse§ 59 (13) 60 (15)
Orug treatment, no. (%)t
Antiplatelet 0 1 (10)
Statin 0 0
Other antihypertensive drugs 3 (30) 3 (30)
Total cholesterol, mean (SO), mgjdL 202 (40) 216 (31)
Triglyceride, mean (SO), mgjdL 123 (35) 113 (57)
HOL-C, mean (SO), mgjdL 58 (17) 54 (14)
Creatinine, mean (SO), mgjdL 0.73 (0.21) 0.74 (0.17)
FPG, mean (SO), mgjdL 102 (9) 106 (29)
Hemoglobin A1c' mean (SO), % 5.34 (0.59) 5.59 (0.78)
Urine albumin/creatinine ratio, mean (SO) 21.7 (20.5) 18.7 (11.4)
ECG voltage, mean (SO), sVl + RV5, mV 3.23 (1.19) 2.84 (0.88)
PWV, mean (SO) 1515 (259) 1561 (278)
CAVI 8.93 (0.93) 8.46 (1.34)
p
0.835
NS
0.602
0.817
NS
NS
0.971
0.705
0.722
NS
NS
NS
0.332
0.713
0.689
0.907
0.734
0.541
0.778
0.345
0.706
0.206
HDL-C =high-density lipoprotein cholesterol; FPG =fasting plasma glucose; ECG =electrocardiographic;
PWV = pulse wave velocity; CAVI = cardia-ankle vascular index.
*No significant between-group differences were found.
t Mann-Whitney U test.
TKruskal-Wallis test.
§ Determined as systolic blood pressure minus diastolic blood pressure.
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EFFECTS OF ANTIHYPERTENSIVE THERAPY ON BLOOD PRESSURE
SBP and DBP decreased significantly in both treatment groups (Figure 1). At the
end of 24 weeks of treatment, the mean reductions in SBP, DBP, and pulse pressure in
the amlodipine group were 14, 10, and 7 mm Hg (P = 0.006,0.005, and 0.139, re-
spectively) and in the candesartan group were 13, 11, and 2 mm Hg (P = 0.033,
0.005, and 0.799, respectively). Reductions in SBP, DBP, and pulse pressure were not
significantly different between the 2 treatment groups.
CHANGES IN ARTERIAL COMPLIANCE AS MEASURED BY
CARDIO-ANKLE VASCULAR INDEX
At baseline, CAVI was not significantly different in the amlodipine group com-
pared with the candesartan group (8.93 [0.93J vs 8.46 [1.34J, respectively). After
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190
180
~ 170
I
E 160
E
c... 150
co
(f) 140
130
120
150 (17)
! *136 (9)!
190
180
170
160
150
140
130
120
152 (18)
f t139 (13)f
Baseline 24 Weeks Baseline 24 Weeks
t
80 (9)
!
91 (15)
f
120
110
100
90
80
70
60
50 J- _
t
83 (11)
~f
93 (13)
!
70
60
50 J- _
120
110
~ 100I
~ 90
§S 80
o
Baseline 24 Weeks Baseline 24 Weeks
Figure 1. Mean (SD) systolic and diastolic blood pressure (SBP and DBP) in the amlo-
dipine and candesartan groups at baseline and after 24 weeks of treatment in
patients with essential hypertension. The decrease in BP was not significantly
different between the 2 treatment groups. *p =0.006 versus baseline; tp =
0.033 versus baseline; '!'P = 0.005 versus baseline.
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24 weeks of treatment, CAVI was decreased significantly from baseline in the amlo-
dipine group (8.60 [1.50}; P = 0.017; decreased in 8 patients), whereas it did not change
significantly in the candesartan group (8.81 [l.20}; decreased in 2 patients) (Figure 2).
The percentage change in CAVI was significantly different in the amlodipine group
compared with the candesartan group (-7.14 [8.83} vs 5.85 [16.0}, respectively; P =
0.038). There was no significant difference between the 2 groups in absolute CAVI
after 24 weeks of treatment. Logistic regression analysis with adjustment for LlSBP,
baseline CAVI, and study dtugs revealed that amlodipine improved CAVI (OR,
18.37; 95% CI, 1.399-2.412; P = 0.027) independent of its SBP-Iowering effects
(OR, 0.940; 95% CI, 0.862-1.025) and baseline CAVI (OR, 1.290; 95% CI,
0.464-3.585).
DISCUSSION
We found that aortic stiffness measured by CAVI improved from baseline after
24 weeks of treatment; both drugs reduced SBP and DBP to the same extent. There
was no significant difference in absolute CAVI after 24 weeks of treatment between
the 2 groups, although the relative change from baseline in CAVI significantly favored
the amlodipine group.
The reduction in compliance of the aorta and elastic arteries has been found to be
a strong independent predictor of cardiovascular events and death. 3- 5 Laurent et aF
found that arterial stiffness evaluated by cfPWV was significantly associated with the
occurrence of all cardiovascular events after adjustment for the Framingham Risk
Score in the cohort study. In a prospective cohort study by Benetos et al,24 the rate of
PWV progression was reported to be higher in patients with hypertension than in nor-
motensive subjects, after adjustment for age, sex, and initial PWV values (171 [20} vs
66 [l6J mmls . y-l; P < 0.00l). They also reported that hypertensive patients whose
blood pressure was well controlled during a 6-year follow-up period had a rate of PWV
Amlodipine Candesartan
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6 ~ 6
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Figure 2. Mean (SD) cardio-ankle vascular index (CAVI) in the amlodipine and candesar-
tan groups at baseline and after 24 weeks of treatment in patients with essen-
tial hypertension. *p =0.017 versus baseline.
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progression similar to that of normotensive subjects (49 [40} vs 81 [I8} mmls . y-l,
respectively), suggesting that blood pressure control is important for attenuating the
hypertension-related progression of arterial stiffness.24
We found arterial stiffness, evaluated by CAVI, was significantly improved in
amlodipine-treated patients, but not in patients receiving candesartan, despite the
blood pressure-lowering effect being similar with the 2 treatments. Logistic regres-
sion analysis showed that the improvement in CAVI in the amlodipine group was
independent of its blood pressure-lowering effect. These results suggest that factors
other than blood pressure are involved in increased arterial stiffness in hypertensive
patients and that amlodipine may prevent arterial stiffening, at least in part, by at-
tenuating blood pressure-independent mechanisms.
Amlodipine has been reported to have pleiotropic effects beyond its blood pres-
sure-lowering action. 19-21 Amlodipine has both antioxidative and antiproliferative
effects on vascular smooth muscle cells and also enhances nitric oxide production by
vascular endothelial cells. The beneficial effects of these blood pressure-independent
pleiotropic effects of amlodipine have been reported in clinical studies. In the
CAMELOT (The Comparison of Amlodipine vs Enalapril to Limit Occurrences of
Thrombosis) study,18 a multicenter, prospective, randomized, open, blinded end point
study, administration of amlodipine for 24 months to normotensive patients with
coronary artery disease resulted in a reduction in adverse cardiovascular events,
whereas no significant treatment effects were observed with enalapril. Furthermore,
the assessment of atherosclerotic plaques by intravascular ultrasonography showed no
progression in plaque volume in patients receiving amlodipine. 25 These results indi-
cated that not only ARBs, but also amlodipine may have antiatherosclerotic effects.
Previous studies have reported that ARBs improve aortic stiffness estimated by
baPWV in hypertensive patients; our findings were inconsistent with these stud-
ies. 26- 28 ARBs also have been reported to have pleiotropic effects, such as antioxida-
tive and antiatherogenic effects. 28,29 Candesartan did not improve CAVI at 24 weeks
of treatment. Another reason why candesartan did not reduce CAVI as much as
amlodipine may be due to study duration. Twenty-four weeks may be too short to
demonstrate the pleiotropic effect of an ARB. Our findings, taken together with the
findings of previous studies, suggest that amlodipine may attenuate hypertension-
related arterial stiffening through both blood pressure-dependent and -independent
mechanisms, whereas the effects of candesartan appeared weaker than amlodipine at
24 weeks.
CAVI has been reported to be useful in evaluating arteriosclerosis and atheroscle-
rosis. 30 Wakabayashi and Masuda31 reported acute-phase reactants, such as C-reactive
protein, serum amyloid A, sialic acid, fibrinogen, and leukocyte count (correlation
coefficients: 0.214 [P < O.OS}; 0.261 [P < 0.01}; 0.308 [P < O.OOI}; 0.300 [P =
0.00l}; and 0.194 [P < O.OS}), were associated with CAVI in patients with type 2 dia-
betes mellitus. We also reported a strong correlation between CAVI and carotid arte-
riosclerosis or stiffness in patients with EHT.t 1 Therefore, our current finding that
treatment with amlodipine for 24 weeks improved CAVI suggests that amlodipine
may have beneficial effects on atherosclerosis in these hypertensive patients.
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LIMITATIONS
The findings were obtained using a small number of patients who were treated for
a relatively short duration. We did not meet the sample size of ;:::25 subjects, which
was determined to be adequate for the analysis. Kubozono et al6 reported that the
mean (SD) CAVI of 1033 consecutive Japanese subjects who were undergoing health
evaluations was 8.3 (1.4). In the present study, the CAVI was reduced to 8.60 (1.5)
after treatment with amlodipine, which was similar to the CAVI in the Japanese cohort.6
We could not exclude the effect of concomitant drugs, such as antiplatelet drugs, al-
though there were no significant differences in medications between the amlodipine
and candesartan groups at baseline and these medications were not changed during
the study. We used the patients' medical record numbers to assign them to treatment,
and this was an open-label trial. Larger, longer, double-blind, randomized controlled
trials are necessary to confirm these findings. There was the possibility of introducing
bias by having the same investigator assess the study outcomes. After 24 weeks of
treatment, the CAVI of the amlodipine group was still numerically larger than the
baseline CAVI of the candesartan group, although the difference was not statistically
significant. Furthermore, there was no significant difference in absolute CAVI be-
tween the 2 groups after 24 weeks, but the relative change was significant in favor of
amlodipine. Finally, because CAVI is a relatively new tool to estimate arterial stiffness,
whether it can be used to predict clinical outcomes remains unknown. However, CAVI
seems to correlate well with measures of hypertensive target organ damage, such as ca-
rotid arterial intima-media thickness and left ventricular diastolic function.
CONCLUSION
These data suggest that amlodipine and candesartan had different effects on aortic
stiffness estimated by CAVI, despite similar effects on brachial blood pressure after
24 weeks of treatment in these Japanese patients with EHT. Larger, longer-term,
randomized studies are needed to evaluate the effect of amlodipine on CAVI.
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